Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Asset Writedowns and Impairment (2019 - 2024)

Historic Asset Writedowns and Impairment for Ani Pharmaceuticals (ANIP) over the last 6 years, with Q4 2024 value amounting to $7.6 million.

  • Ani Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $7.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.6 million, marking a year-over-year increase of 76010000.0%. This contributed to the annual value of $7.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Asset Writedowns and Impairment of $7.6 million as of Q4 2024.
  • Ani Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $7.6 million during Q4 2024, with a 5-year trough of -$1000.0 in Q3 2022.
  • Its 4-year average for Asset Writedowns and Impairment is $2.1 million, with a median of $341000.0 in 2020.
  • Per our database at Business Quant, Ani Pharmaceuticals' Asset Writedowns and Impairment surged by 35466.67% in 2020 and then soared by 59618.77% in 2021.
  • Over the past 4 years, Ani Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $341000.0 in 2020, then surged by 596.19% to $2.4 million in 2021, then tumbled by 100.04% to -$1000.0 in 2022, then surged by 760100.0% to $7.6 million in 2024.
  • Its Asset Writedowns and Impairment was $7.6 million in Q4 2024, compared to -$1000.0 in Q3 2022 and $2.4 million in Q4 2021.